Exelixis IncEXEL
Price$57.94Intrinsic value$75.9131% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $2.4B+12.3% YoYTTM through 3 Jul 2026
Net Income $860.6M+65.1% YoYTTM through 3 Jul 2026
Free Cash Flow $1.2BTTM through 3 Jul 2026

Margins

Current
Gross Margin96.7%
EBITDA Margin41.0%
Operating Margin42.3%
Net Margin35.3%

Returns

46.7%ROE
34.5%ROA

Balance Sheet Health

Debt / Equity0.34x
Current Ratio3.26x
Cash & Equivalents$281.4M

Quality Metrics

Altman Z-Score15.83
Piotroski F-Score7 / 9
FCF Margin48.1%
Rule of 4052.9
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'20'21'21'22'23'25'26
FY2026: $2.3B
Diluted EPS$3.18TTM
'20'21'21'22'23'25'26
FY2026: $2.78

Dividend

No dividend

Capital Allocation

R&D Spend$824.3M
Capex Intensity0.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.